Morbid Obesity
Pipeline by Development Stage
Drug Modality Breakdown
Metabolic Diseases is a $70.5B mature market dominated by diabetes and anticoagulation therapies with sustained blockbuster momentum.
Key Trends
- GLP-1 agonists (Ozempic, Mounjaro) driving explosive growth and market consolidation
- SGLT2 inhibitors expanding beyond diabetes into cardio-renal indications
- Significant patent cliff risk 2027-2029 for DPP-4 inhibitors (Januvia) and older insulins
Career Verdict
Excellent opportunity for specialists seeking stable, high-revenue exposure with strong hiring momentum in commercial and engineering roles.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 26% | Launch | Stable | 15.0yr |
| 2 | OZEMPIC (semaglutide) | Novo Nordisk | $9.2B | 13% | Peak | Growing | 12.4yr |
| 3 | JARDIANCE (empagliflozin) | Boehringer Ingelheim | $8.8B | 12% | Peak | Growing | 8.6yr |
| 4 | TRULICITY (dulaglutide) | Eli Lilly and Company | $7.4B | 10% | Peak | Stable | |
| 5 | FARXIGA (dapagliflozin) | AstraZeneca | $4.3B | 6% | Peak | Growing | 15.4yr |
Drug Class Breakdown
stable, mature franchise
rapid growth, expanding indications
growing, cardio-renal expansion
stable, generics pressure
declining, patent cliff 2027
Career Outlook
GrowingMetabolic diseases offers stable, high-value career trajectory with blockbuster product revenue supporting competitive compensation and long-term job security. Commercial and field-based roles dominate hiring, reflecting the shift toward patient access, digital health, and device integration in diabetes management. Patent cliff exposure in DPP-4 class (2027-2029) creates near-term volatility for Merck but limited impact on overall market given GLP-1 dominance.
Breaking In
Target device companies (Insulet, Abbott) or diagnostic firms for entry-level roles if traditional pharma hiring is limited; strong foundation in diabetes biology and HbA1c/CGM metrics will accelerate credibility.
For Experienced Professionals
Experienced professionals should prioritize GLP-1 franchise or SGLT2 indication expansion roles; avoid Merck DPP-4-focused assignments given 2027 patent cliff, unless willing to transition to next-generation pipeline.
In-Demand Skills
Best For
Hiring Landscape
Hiring activity is concentrated in commercial roles (166 positions) and engineering (126 positions), driven by device makers (Insulet: 270 jobs) and diagnostic companies (Abbott: 154 jobs) rather than traditional pharma. Sanofi leads pharma hiring with 42 metabolic-focused positions, but specialized roles in clinical operations remain constrained. Salary expectations range from $153K (Clinical Ops) to $274K (Manufacturing), with strong compensation for commercial and quality roles.
Top Hiring Companies
By Department
Strongest hiring momentum in device/delivery and commercial infrastructure; traditional pharma R&D roles remain limited despite blockbuster pipeline.
Competitive Landscape
15 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 22 trials with date data
Clinical Trials (22)
Total enrollment: 1,689 patients across 22 trials
Dosing Obese With Noxafil® Under a Trial (DONUT)
Micafungin Pharmacokinetics in Obese Patients
Surgical Conditions During Laparoscopic Bariatric Surgery
Trial Assessing the Immunogenicity and Safety of Two Influenza Vaccine Strategies Among Severe Obese Adult Patients
Early Feasibility for Safety & Device Functionality of SFM Anastomosis Device Used in 3 Procedures (SNAP-S) or (SNAP-PS) or (J-J)
Pilot Study of the Endolumik Gastric Calibration Tube for Bariatric Surgery
Nonresponders by the Session Order Factor
McGrath Videolaryngoscopy and Direct Laryngoscopy in Morbidly Obese Patients
Resistance Training in Patients With Morbid Obesity
Oxygen Reserve Index: Utility as Early Warning for Desaturation in Morbidly Obese Patients
Transmitted Light Tissue Thickness Analysis (TiLTT)
Effect of Positive End Expiratory Pressure at the Time of Induction in Morbidly Obese Patients
Multicenter Prospective Randomized Controlled Trial of Plicated Laparoscopic Adjustable Gastric Banding
Treatment of Low Metabolic Rate Following Bariatric Surgery
Clinical and Economic Outcomes in Laparoscopic Sleeve Gastrectomy Versus Roux-en-Y Gastric Bypass Surgery
Prospective Case-Series of Ligasure Advance Pistol Grip and LigaSure Blunt Tip
Oseltamivir Pharmacokinetics in Morbid Obesity
European Union (EU) Post-Market Study on Easyband®
Appetite Suppression / Hormone Study Control Group
Study to Determine Incidence of Hypoventilation in Patients Who Have Undergone Gastric Bypass
Study Evaluating Metabolic Syndrome in Subjects Undergoing Gastric Bypass Bariatric Syndrome
Related Jobs in Metabolic Diseases
Seattle Territory Business Leader
Phoenix North Territory Business Leader
Territory Manager - Virginia Beach, VA (Field Based)
Software Engineer - Full Stack
Clinical Services Manager - LA West (Field Base)
Portland Clinical Diabetes Specialist
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.